$mnkd baggies excited - founder of Samson hair restoration, who founded Vdex and is mnkd shareholder, feels vdex is disrespected and wants wholesale priced afrezza as "full right" pharmaceutical distributer - because their 3 places in CA and 3 in NM "work". LOL
Folks whining about $mnkd leadership again. The real problem is Afrezza itself. Despite anecdotal stories, likely from bagholders or shills the drug is simply unwanted and doesn't match current therapies. There's a reason Alkermes, $LLY $PFE, Aradigm, $NVO gave up inhaled insulin
@SEC_Enforcement watch $MNKD for possible #REAL_TIME stock pumper manipulation. @US_FDA#FDA Office of Prescription Drug Promotion watch $mnkd social media for false and misleading claims denying risks and dangers of Black Box afrezza. Thank You.
So $mnkd pays Zacks SCR $10's of thousands a year to write " research reports ". Recent paid report is rehash of the June10 poster on P2 N=15 ped study that will eventually have 46 subjects, was started in 2015 and is yrs from completion.
$mnkd Wk of 6/7/19 Nrx 332 Rrx 337. The official FDA Afrezza Label is clear cut - "AFREZZA provided less HbA1c reduction than insulin aspart, and the difference was statistically significant. More subjects in the insulin aspart group achieved the HbA1c target of ≤7% "
$mnkd baggies complaining about ceo again. LOL. The problem isn't the ceo. The problem is afrezza. It's clearly a dud. The top ceo in biopharm could come aboard and nothing would change. Afrezza scripts would continue to be poor nowhere near being or becoming even a niche drug.
$mnkd Wk ending 4/5. Scripts NRx 247 RRx 335. Do or die year for 28 year old company with only 1 drug approved 5 yrs ago. Afrezza not making required money. Weak financials.
@_chuck956 I believe the official SEC 10Q filing signed by the CEO and CFO that states throughout " substantial doubts about continuing as a going concern". I also believe they have a severe cash crisis and afrezza is a flop.
MNKD states as does their outside auditors there's substantial doubts in their ability to continue as a going concern in numerous reports filed with the SEC... Believe it or not afrezza sales stink. That's for the record.
Smart $mnkd longs don't bother with 10Q reports. Just a bunch of numbers that are hard to understand and big words. The best way to get the facts is by what management says in their p.r.
$arna APD371 Not a Big Deal. Testing limited to crohn's stomach pain. Many exclusions on subjects. Trouble recruiting. N=20. Long hx of cb2 fails.
#pharma#stocks#biotechworld#oprah#drphil $AGN $nktr
Expecting major FDA scrutiny of $ARNA tiny mostly Outsouced, Eastern Euro S1P1 study whenever P2a results released with recent FDA action on celg's product